Both well-established and small, clinical-stage pharma companies are investing heavily to be able to someday compete with ...

Novo Nordisk A/S and Eli Lilly & Co, the pharmaceutical giants dominating the global obesity drug market, now face their ...

Novo Nordisk (NVO) and Eli Lilly & Co. (LLY), the global leaders in obesity medications, are now facing their first major ...

Top executives ignored warnings that the company was not sufficiently prepared for the launch of its weight-loss drug Wegovy, ...

VK2735 shows strong early weight loss data, positioning Viking Therapeutics as a potential third major player in the booming GLP-1 obesity drug market. Learn more on VKTX stock here.

Due to popularity of the medications, GLP-1s were in short supply up until recently. Obesity is a common issue among ...

The Howard County Board of Education is suing Eli Lilly and Co., Novo Nordisk, CVS, United Health group and several other ...

Another major insurance change coming next year will affect another large swath of Dushay’s patients: In January, BCBS ...

A PIL has claimed that licences for these drugs were issued without adequate data or India-specific trials and studies, ...

CVS Caremark will stop covering Eli Lilly's Zepbound, a weight loss drug, due to insurance company changes. Patients are outraged and concerned.

Eli Lilly and Company (NYSE:LLY) is one of the 12 stocks that will make you rich in 10 years. On June 23, Truist Securities ...